| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64cc63b420dcef3560583c7206af2c6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0847d4cab0e81b67a7710488a3fa3c7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ba5557262d9bf8846bbaa2fe725462c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate |
2016-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf175f84fe7f053f1bd56bf6dab73159
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16b6ca926c1a063c754a3d788c88046c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fd7cf4bca3792a74ca909cab1d10add
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07accfd087ea4215a2ef9a2d001f5586 |
| publicationDate |
2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2016387192-B2 |
| titleOfInvention |
Joint application of statin and adrenocortical hormone for treating chronic subdural hematoma |
| abstract |
Provided is a joint application of a statin and a adrenocortical hormone for preparing a pharmaceutical product for treating a chronic subdural hematoma. The pharmaceutical product provided by the invention is able to accelerate hematoma absorption and improve a therapeutic effect of a single oral administration of a statin-based pharmaceutical product. The quantity of an adrenocortical hormone-based pharmaceutical product used is 1/10 of the quantity used in a high-dose hormonal therapy. |
| priorityDate |
2016-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |